Read Frequently Asked Questions
Why and How - Verification of Compendial Methods - USP <1226>
This webinar will provide an in-depth discussion of USP <1226>, 'Verification of Compendial Methods' requirements. We will discuss FDA 483s on the subject of Method Verification to understand current FDA expectations.
Product ID: 701752
Training Level: Intermediate to Advanced
Why Should You Attend:
This webinar will provide an in-depth discussion of USP <1226>, 'Verification of Compendial Methods' requirements. Conditions under which Methods can be classified as 'basic' and not require verification will be discussed. The factors under actual conditions of use which impact method performance and make method verification necessary will be addressed. FDA 483s on the subject of Method Verification will be discussed to understand current FDA expectations for verification of compendial methods.
Areas Covered in the Webinar:
- FDA 483s related to method verification.
- Requirements of USP <1226>, 'Verification of Compendial Methods'
- What are the current FDA expectations related to method verification.
- What are the factors which impact method performance under actual condition of use?
Who Will Benefit:
- QC personnel
- QC Supervisors and Management
- QA personnel
- QA Management
- Documentation management specialists
- Regulatory affairs personnel
- R&D Lab personnel
- R&D Lab Supervisors
Dr. Subbarao, holds a Ph.D. in Bio-organic Chemistry. She is currently a Senior Consultant with the Biologics Consulting Group specializing in Analytical, Stability, CMC and GLP/GMP Quality Systems. Her hands-on industrial experience covers stability and laboratory cGMP systems for both biologics and conventional drugs. As a consultant she has assisted pharma and biotech organizations in evaluation of analytical methods and method validation for a wide range of products ranging from conventional drugs to well characterized proteins and vaccines, from pre-clinical phase to commercial phases. She has been involved several times over her career in projects to setup or upgrade cGMP/GLP complaint Quality Systems for laboratory and stability programs for products during development and in commercial phase. She serves on the AAPS Stability Focus Group Steering Committee.
ComplianceOnline would process/provide refund only if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs."
For substitution, please email firstname.lastname@example.org or call +1-650-620-3937.
This training hasn't been reviewed yet.
Best Practices for Conducting OOS Investigations (in Pharmaceutical Laboratories) Designing Effective and Efficient Extractables or Leachables Studies for Biologics Particulates in Biological products - Why test them and what are the new reporting requirements? Forced Degradation Studies/ Biologics Stability Programs for Biopharmaceuticals